MGAT5 and inflammatory bowel disease: Treatment of these mice with high concentrations of N-acetylglucosamine (GlcNAc) increased GnT-V-mediated N-glycan branching and inhibited TCR activation and autoimmune responses in mouse models of EAE, IBD, and type 1 diabetes.